BackAvalo Therapeutics Overview

Avalo Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for AVTX.

Quarterly EBIT

-$20.90M
42.48% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$80.59M
68.69% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)